Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% OTC

Glenmark Therapeutics Inc., USA (Glenmark) has announced it has launched Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC); compare to the active ingredient in Pataday® Twice Daily Relief.

According to Nielsen® syndicated data for the latest 52 weeks' period ending July 13, 2024, the Pataday® Twice Daily Relief (OTC) market achieved annual sales of approximately $26.4 million*.

Commenting on the launch, Fabio Moreno, Head - OTC Sales & Marketing, Glenmark Pharmaceuticals Inc. said, "We are excited to announce the launch of Olopatadine Ophthalmic Solution USP, 0.1%, addressing the growing demand for a new supplier in this category. This addition highlights our commitment to meeting market needs and providing high-quality overthe-counter solutions for our customers."

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 1632.15 as compared to the previous close of Rs. 1564.70. The total number of shares traded during the day was 40369 in over 3576 trades.

The stock hit an intraday high of Rs. 1639.15 and intraday low of 1567.15. The net turnover during the day was Rs. 65266572.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 GlenmarkTherapeutics OlopatadineHydrochloride OphthalmicSolution